Get the Stockscreener App
60.49
3.31%
1.94
After Hours:
60.40
-0.09
-0.15%
Veracyte Inc stock is traded at $60.49, with a volume of 3.33M.
It is up +3.31% in the last 24 hours and up +36.82% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
See More
Previous Close:
$58.55
Open:
$58.55
24h Volume:
3.33M
Relative Volume:
2.99
Market Cap:
$4.83B
Revenue:
$541.74M
Net Income/Loss:
$88.01M
P/E Ratio:
55.69
EPS:
1.0862
Net Cash Flow:
$155.34M
1W Performance:
+12.79%
1M Performance:
+36.82%
6M Performance:
+42.36%
1Y Performance:
+125.62%
1-Day Range:
$58.06
$60.83
1-Week Range:
$52.36
$60.83
52-Week Range:
$22.61
$60.83
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
60.49 | 4.67B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 187.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.19 | 136.75B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
551.50 | 43.78B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.01 | 38.27B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.91 | 37.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Underweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Hold |
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte, Inc. Actuals & Estimates (TRADEGATE:12V) - TradingView
Veracyte, Inc. Actuals & Estimates (MUN:12V) - TradingView
Veracyte, Inc. Actuals & Estimates (DUS:12V) - TradingView
Q1 2025 Veracyte Inc Earnings Call Transcript - GuruFocus
Q4 2025 Veracyte Inc Earnings Call Transcript - GuruFocus
Q2 2025 Veracyte Inc Earnings Call Transcript - GuruFocus
Q3 2025 Veracyte Inc Earnings Call Transcript - GuruFocus
Veracyte, Inc. Actuals & Estimates (NASDAQ:VCYT) - TradingView
Veracyte Inc (VCYT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
VCYT Forecast — Price Target — Prediction for 2027 - TradingView
12V Forecast — Price Target — Prediction for 2027 - TradingView
Veracyte Inc (VCYT) Shares Surge 3.1% -- What GF Score of 75 Tel - GuruFocus
Veracyte Jumps 7.2% Amid Sector-Wide Rally - AlphaStreet
Veracyte stock hits 52-week high at 55.32 USD - Investing.com
Veracyte stock hits 52-week high at 55.32 USD By Investing.com - Investing.com Canada
Insider Sell Alert: Karin Eastham Sells Shares of Veracyte Inc (VCYT) - GuruFocus
Form 4 Veracyte Inc For: 22 June By Investing.com - Investing.com South Africa
Veracyte director Karin Eastham sells $197,234 in stock By Investing.com - Investing.com South Africa
Veracyte director Karin Eastham sells $197,234 in stock - Investing.com
Veracyte (VCYT) director logs 3,729-share Rule 10b5-1 stock sale - Stock Titan
VCYT News | VERACYTE INC (NASDAQ:VCYT) - ChartMill
[144] VERACYTE, INC. SEC Filing - Stock Titan
VCYT|Veracyte Inc|Price:53.630|Chg%:2.34 - TradingKey
Veracyte Inc (VCYT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Veracyte Inc (VCYT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Veracyte Inc (VCYT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Veracyte Inc (VCYT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Veracyte Inc (VCYT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Veracyte Inc (VCYT) Institutional Confidence - TradingKey
Veracyte Inc (VCYT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Veracyte Inc (VCYT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Veracyte stock hits 52-week high at 50.81 USD By Investing.com - Investing.com South Africa
Is Veracyte Inc (VCYT) Overvalued After 3.5% Rally? GF Value Say - GuruFocus
Veracyte stock hits 52-week high at 50.81 USD - Investing.com
High Growth Momentum Breakout Setup: Veracyte Inc (NASDAQ:VCYT) - ChartMill
Veracyte (VCYT) director Jens Holstein awarded 5,272 restricted stock units - Stock Titan
Veracyte (VCYT) director Eliav Barr receives 5,272 restricted stock units - Stock Titan
Director at Veracyte (VCYT) receives grant of 5,272 restricted stock units - Stock Titan
Evan Jones of Veracyte (NASDAQ: VCYT) receives 5,272 restricted stock units - Stock Titan
Director at VERACYTE, INC. (VCYT) awarded 5,272 restricted stock units - Stock Titan
Veracyte (VCYT) director Robert Epstein receives 5,272-share RSU grant - Stock Titan
[Form 4] VERACYTE, INC. Insider Trading Activity - Stock Titan
Veracyte (VCYT) director awarded 5,272 RSUs vesting over one year - Stock Titan
Veracyte, Inc. 2023 Equity Incentive Plan Amended – SEC 8-K Filing Details and Company Information - Minichart
Veracyte shareholders endorse board, pay and incentive plans - The Globe and Mail
FMR LLC's Strategic Acquisition of Veracyte Inc Shares - GuruFocus
Veracyte (VCYT) investors back 3.5M-share equity plan increase and elect full board - Stock Titan
Veracyte (NASDAQ:VCYT) Hits New 12-Month HighHere's Why - MarketBeat
Why Veracyte (VCYT) is a top momentum stock for the long term - MSN
Here's why Veracyte (VCYT) is a strong growth stock - MSN
Assessing Veracyte (VCYT) Valuation After New Prosigna Launch And Decipher Prostate Clinical Milestones - Sahm
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.76%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):